ID EHMT1_MOUSE Reviewed; 1296 AA.
AC Q5DW34; A2AIS3; A2AIS4; Q5EBR1; Q6PGM0;
DT 08-MAR-2011, integrated into UniProtKB/Swiss-Prot.
DT 08-MAR-2011, sequence version 2.
DT 04-NOV-2026, entry version 169.
DE RecName: Full=Histone-lysine N-methyltransferase EHMT1;
DE EC=2.1.1.- {ECO:0000269|PubMed:15774718, ECO:0000269|PubMed:24196706};
DE EC=2.1.1.367 {ECO:0000269|PubMed:15774718};
DE AltName: Full=Euchromatic histone-lysine N-methyltransferase 1;
DE Short=Eu-HMTase1;
DE AltName: Full=G9a-like protein 1;
DE Short=GLP;
DE Short=GLP1;
DE AltName: Full=Lysine N-methyltransferase 1D;
GN Name=Ehmt1 {ECO:0000303|PubMed:24196706, ECO:0000312|MGI:MGI:1924933};
GN Synonyms=Euhmtase1, Glp, Kmt1d;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC Murinae; Mus; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP SUBCELLULAR LOCATION, DISRUPTION PHENOTYPE, INTERACTION WITH EHMT2, AND
RP TISSUE SPECIFICITY.
RX PubMed=15774718; DOI=10.1101/gad.1284005;
RA Tachibana M., Ueda J., Fukuda M., Takeda N., Ohta T., Iwanari H.,
RA Sakihama T., Kodama T., Hamakubo T., Shinkai Y.;
RT "Histone methyltransferases G9a and GLP form heteromeric complexes and are
RT both crucial for methylation of euchromatin at H3-K9.";
RL Genes Dev. 19:815-826(2005).
RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=C57BL/6J;
RX PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA Eichler E.E., Ponting C.P.;
RT "Lineage-specific biology revealed by a finished genome assembly of the
RT mouse.";
RL PLoS Biol. 7:E1000112-E1000112(2009).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 34-1296 (ISOFORM 2), AND
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 89-1296 (ISOFORM 3).
RC STRAIN=C57BL/6J; TISSUE=Brain;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [4]
RP FUNCTION, AND MUTAGENESIS OF TYR-1153; 1198-ASN--CYS-1201; CYS-1201 AND
RP TYR-1240.
RX PubMed=18818694; DOI=10.1038/emboj.2008.192;
RA Tachibana M., Matsumura Y., Fukuda M., Kimura H., Shinkai Y.;
RT "G9a/GLP complexes independently mediate H3K9 and DNA methylation to
RT silence transcription.";
RL EMBO J. 27:2681-2690(2008).
RN [5]
RP DOMAIN ANK REPEATS, AND INTERACTION WITH RELA.
RX PubMed=21131967; DOI=10.1038/ni.1968;
RA Levy D., Kuo A.J., Chang Y., Schaefer U., Kitson C., Cheung P., Espejo A.,
RA Zee B.M., Liu C.L., Tangsombatvisit S., Tennen R.I., Kuo A.Y., Tanjing S.,
RA Cheung R., Chua K.F., Utz P.J., Shi X., Prinjha R.K., Lee K., Garcia B.A.,
RA Bedford M.T., Tarakhovsky A., Cheng X., Gozani O.;
RT "Lysine methylation of the NF-kappaB subunit RelA by SETD6 couples activity
RT of the histone methyltransferase GLP at chromatin to tonic repression of
RT NF-kappaB signaling.";
RL Nat. Immunol. 12:29-36(2011).
RN [6]
RP RETRACTED PAPER.
RX PubMed=22629437; DOI=10.1371/journal.pone.0037647;
RA Wang J., Abate-Shen C.;
RT "The MSX1 homeoprotein recruits G9a methyltransferase to repressed target
RT genes in myoblast cells.";
RL PLoS ONE 7:e37647-e37647(2012).
RN [7]
RP RETRACTION NOTICE OF PUBMED:22629437.
RX PubMed=37405986; DOI=10.1371/journal.pone.0288411;
RG PLOS ONE Editors;
RL PLoS ONE 18:e0288411-e0288411(2023).
RN [8]
RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH PRDM16, AND MUTAGENESIS OF
RP 1198-ASN-HIS-1199.
RX PubMed=24196706; DOI=10.1038/nature12652;
RA Ohno H., Shinoda K., Ohyama K., Sharp L.Z., Kajimura S.;
RT "EHMT1 controls brown adipose cell fate and thermogenesis through the
RT PRDM16 complex.";
RL Nature 504:163-167(2013).
RN [9] {ECO:0000305}
RP FUNCTION, AND INTERACTION WITH BAZ2B.
RX PubMed=32103178; DOI=10.1038/s41586-020-2037-y;
RA Yuan J., Chang S.Y., Yin S.G., Liu Z.Y., Cheng X., Liu X.J., Jiang Q.,
RA Gao G., Lin D.Y., Kang X.L., Ye S.W., Chen Z., Yin J.A., Hao P., Jiang L.,
RA Cai S.Q.;
RT "Two conserved epigenetic regulators prevent healthy ageing.";
RL Nature 579:118-122(2020).
RN [10]
RP FUNCTION, AND INTERACTION WITH PRDM16.
RX PubMed=35978186; DOI=10.1038/s41586-022-05067-4;
RA Wang Q., Li H., Tajima K., Verkerke A.R.P., Taxin Z.H., Hou Z., Cole J.B.,
RA Li F., Wong J., Abe I., Pradhan R.N., Yamamuro T., Yoneshiro T.,
RA Hirschhorn J.N., Kajimura S.;
RT "Post-translational control of beige fat biogenesis by PRDM16
RT stabilization.";
RL Nature 609:151-158(2022).
CC -!- FUNCTION: Histone methyltransferase that specifically mono-, di- and
CC trimethylates 'Lys-9' of histone H3 (H3K9me1, H3K9me2 and H3K9me3,
CC respectively) in euchromatin (PubMed:15774718, PubMed:24196706). H3K9me
CC represents a specific tag for epigenetic transcriptional repression by
CC recruiting HP1 proteins to methylated histones (PubMed:15774718,
CC PubMed:24196706). Also weakly methylates 'Lys-27' of histone H3
CC (H3K27me) (PubMed:15774718). Also required for DNA methylation, the
CC histone methyltransferase activity is not required for DNA methylation,
CC suggesting that these 2 activities function independently
CC (PubMed:18818694). Probably targeted to histone H3 by different DNA-
CC binding proteins like E2F6, MGA, MAX and/or DP1 (By similarity). During
CC G0 phase, it probably contributes to silencing of MYC- and E2F-
CC responsive genes, suggesting a role in G0/G1 transition in cell cycle
CC (By similarity). Involved in the differentiation of myoblastic
CC precursors into brown adipose cells: following recruitment to chromatin
CC by PRDM16, mediates formation of H3K9me2 and H3K9me3, inhibiting the
CC expression of white adipose-selective genes (PubMed:24196706). Also
CC involved in the differentiation of beige adipocytes from white adipose
CC cells following recruitment by PRDM16 (PubMed:35978186). EHMT1 also
CC promotes protein stabilization of PRDM16, by preventing PRDM16
CC ubiquitination and degradation (PubMed:24196706). In addition to the
CC histone methyltransferase activity, also methylates non-histone
CC proteins: mediates dimethylation of 'Lys-373' of p53/TP53 (By
CC similarity). Represses the expression of mitochondrial function-related
CC genes, perhaps by occupying their promoter regions, working in concert
CC with probable chromatin reader BAZ2B (PubMed:32103178).
CC {ECO:0000250|UniProtKB:Q9H9B1, ECO:0000269|PubMed:15774718,
CC ECO:0000269|PubMed:18818694, ECO:0000269|PubMed:24196706,
CC ECO:0000269|PubMed:32103178, ECO:0000269|PubMed:35978186}.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=L-lysyl(9)-[histone H3] + S-adenosyl-L-methionine = N(6)-
CC methyl-L-lysyl(9)-[histone H3] + S-adenosyl-L-homocysteine + H(+);
CC Xref=Rhea:RHEA:60280, Rhea:RHEA-COMP:15542, Rhea:RHEA-COMP:15546,
CC ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57856,
CC ChEBI:CHEBI:59789, ChEBI:CHEBI:61929; EC=2.1.1.367;
CC Evidence={ECO:0000269|PubMed:15774718};
CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:60281;
CC Evidence={ECO:0000269|PubMed:15774718};
CC -!- CATALYTIC ACTIVITY:
CC Reaction=N(6)-methyl-L-lysyl(9)-[histone H3] + S-adenosyl-L-methionine
CC = N(6),N(6)-dimethyl-L-lysyl(9)-[histone H3] + S-adenosyl-L-
CC homocysteine + H(+); Xref=Rhea:RHEA:60284, Rhea:RHEA-COMP:15541,
CC Rhea:RHEA-COMP:15542, ChEBI:CHEBI:15378, ChEBI:CHEBI:57856,
CC ChEBI:CHEBI:59789, ChEBI:CHEBI:61929, ChEBI:CHEBI:61976;
CC Evidence={ECO:0000269|PubMed:15774718, ECO:0000269|PubMed:24196706};
CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:60285;
CC Evidence={ECO:0000269|PubMed:15774718, ECO:0000269|PubMed:24196706};
CC -!- CATALYTIC ACTIVITY:
CC Reaction=N(6),N(6)-dimethyl-L-lysyl(9)-[histone H3] + S-adenosyl-L-
CC methionine = N(6),N(6),N(6)-trimethyl-L-lysyl(9)-[histone H3] + S-
CC adenosyl-L-homocysteine + H(+); Xref=Rhea:RHEA:60288, Rhea:RHEA-
CC COMP:15538, Rhea:RHEA-COMP:15541, ChEBI:CHEBI:15378,
CC ChEBI:CHEBI:57856, ChEBI:CHEBI:59789, ChEBI:CHEBI:61961,
CC ChEBI:CHEBI:61976; Evidence={ECO:0000269|PubMed:24196706};
CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:60289;
CC Evidence={ECO:0000269|PubMed:24196706};
CC -!- ACTIVITY REGULATION: Methyltransferase activity is inhibited by BIX-
CC 01294. Efficiently inhibited by compound E72, a BIX-01294 derivative in
CC which the diazepane ring and the benzyl are replaced with a 3-
CC dimethylaminopropyl and a 5-aminopentyl group at sites B and C,
CC respectively (By similarity). {ECO:0000250|UniProtKB:Q9H9B1}.
CC -!- SUBUNIT: Interacts with WIZ. Part of the E2F6.com-1 complex in G0 phase
CC composed of E2F6, MGA, MAX, TFDP1, CBX3, BAT8, EHMT1, RING1, RNF2,
CC MBLR, L3MBTL2 and YAF2. Interacts with MPHOSPH8 (By similarity).
CC Interacts with CDYL. Interacts with REST only in the presence of CDYL.
CC Part of a complex containing at least CDYL, REST, WIZ, SETB1, EHMT1 and
CC EHMT2 (By similarity). Heterodimer; heterodimerizes with EHMT2.
CC Interacts (via ANK repeats) with RELA (when monomethylated at 'Lys-
CC 310'). Interacts with BAZ2B (PubMed:32103178). Interacts with PRDM16;
CC promoting EHMT1 recruitment to chromatin, differentiation of brown
CC adipose cells and stabilization of PRDM16 (PubMed:24196706,
CC PubMed:35978186). {ECO:0000250|UniProtKB:Q9H9B1,
CC ECO:0000269|PubMed:15774718, ECO:0000269|PubMed:21131967,
CC ECO:0000269|PubMed:24196706, ECO:0000269|PubMed:32103178,
CC ECO:0000269|PubMed:35978186}.
CC -!- INTERACTION:
CC Q5DW34-1; A2A935-3: Prdm16; NbExp=2; IntAct=EBI-16080518, EBI-16080455;
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15774718}. Chromosome
CC {ECO:0000269|PubMed:15774718, ECO:0000269|PubMed:24196706}.
CC Note=Associates with euchromatic regions.
CC {ECO:0000269|PubMed:15774718}.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=3;
CC Name=1;
CC IsoId=Q5DW34-1; Sequence=Displayed;
CC Name=2;
CC IsoId=Q5DW34-2; Sequence=VSP_040724, VSP_040725;
CC Name=3;
CC IsoId=Q5DW34-3; Sequence=VSP_040726;
CC -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:15774718}.
CC -!- DOMAIN: The ANK repeats specifically recognize and bind H3K9me1 and
CC H3K9me2 (By similarity). They also specifically recognize and bind RELA
CC subunit of NF-kappa-B, when RELA is monomethylated at 'Lys-310'
CC (PubMed:21131967). {ECO:0000250|UniProtKB:Q9H9B1,
CC ECO:0000269|PubMed:21131967}.
CC -!- DOMAIN: The SET domain mediates interaction with WIZ.
CC {ECO:0000250|UniProtKB:Q9H9B1}.
CC -!- DOMAIN: In the pre-SET domain, Cys residues bind 3 zinc ions that are
CC arranged in a triangular cluster; some of these Cys residues contribute
CC to the binding of two zinc ions within the cluster.
CC {ECO:0000250|UniProtKB:Q9H9B1}.
CC -!- DISRUPTION PHENOTYPE: Embryos die around E9.5. Levels of H3K9me1 and
CC H3K9me2 are drastically reduced (PubMed:15774718). Conditional deletion
CC in brown adipocytes precursors causes a severe loss of brown fat and
CC induces muscle differentiation through demethylation of H3K9me2 and
CC H3K9me3 (PubMed:24196706). {ECO:0000269|PubMed:15774718,
CC ECO:0000269|PubMed:24196706}.
CC -!- SIMILARITY: Belongs to the class V-like SAM-binding methyltransferase
CC superfamily. {ECO:0000255|PROSITE-ProRule:PRU00190}.
CC -!- CAUTION: Thought to interact with MSX1. However the paper has been
CC retracted over concerns of image tampering.
CC {ECO:0000305|PubMed:37405986}.
CC -!- SEQUENCE CAUTION:
CC Sequence=CAM22112.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AB205007; BAD90007.1; -; mRNA.
DR EMBL; AL732525; CAM22112.1; ALT_INIT; Genomic_DNA.
DR EMBL; AL732525; CAM22113.1; -; Genomic_DNA.
DR EMBL; AL732525; CAM22114.1; -; Genomic_DNA.
DR EMBL; BC056938; AAH56938.1; -; mRNA.
DR EMBL; BC089302; AAH89302.1; -; mRNA.
DR CCDS; CCDS15740.1; -. [Q5DW34-1]
DR CCDS; CCDS59634.1; -. [Q5DW34-2]
DR CCDS; CCDS59636.1; -. [Q5DW34-3]
DR RefSeq; NP_001012536.2; NM_001012518.3. [Q5DW34-1]
DR RefSeq; NP_001103156.1; NM_001109686.2. [Q5DW34-2]
DR RefSeq; NP_001103157.1; NM_001109687.2. [Q5DW34-3]
DR AlphaFoldDB; Q5DW34; -.
DR SMR; Q5DW34; -.
DR BioGRID; 218847; 24.
DR DIP; DIP-49000N; -.
DR DIP; DIP-59572N; -.
DR FunCoup; Q5DW34; 5089.
DR IntAct; Q5DW34; 11.
DR STRING; 10090.ENSMUSP00000119057; -.
DR GlyCosmos; Q5DW34; 1 site, No reported glycans.
DR GlyGen; Q5DW34; 2 sites, 1 O-linked glycan (1 site).
DR iPTMnet; Q5DW34; -.
DR PhosphoSitePlus; Q5DW34; -.
DR SwissPalm; Q5DW34; -.
DR jPOST; Q5DW34; -.
DR PaxDb; 10090-ENSMUSP00000119057; -.
DR PeptideAtlas; Q5DW34; -.
DR ProteomicsDB; 277570; -. [Q5DW34-1]
DR ProteomicsDB; 277571; -. [Q5DW34-2]
DR ProteomicsDB; 277572; -. [Q5DW34-3]
DR Pumba; Q5DW34; -.
DR Antibodypedia; 32511; 547 antibodies from 35 providers.
DR DNASU; 77683; -.
DR Ensembl; ENSMPUT00000015409; ENSMPUP00000015170; ENSMPUG00000015280.
DR Ensembl; ENSMUST00000046227.12; ENSMUSP00000046077.6; ENSMUSG00000036893.19. [Q5DW34-3]
DR Ensembl; ENSMUST00000114432.9; ENSMUSP00000110075.3; ENSMUSG00000036893.19. [Q5DW34-2]
DR Ensembl; ENSMUST00000147147.8; ENSMUSP00000119057.3; ENSMUSG00000036893.19. [Q5DW34-1]
DR GeneID; 77683; -.
DR KEGG; mmu:77683; -.
DR UCSC; uc008iph.4; mouse. [Q5DW34-3]
DR UCSC; uc008ipi.4; mouse. [Q5DW34-1]
DR UCSC; uc012brr.3; mouse. [Q5DW34-2]
DR AGR; MGI:1924933; -.
DR CTD; 79813; -.
DR MGI; MGI:1924933; Ehmt1.
DR VEuPathDB; HostDB:ENSMUSG00000036893; -.
DR eggNOG; KOG1082; Eukaryota.
DR GeneTree; ENSGT00940000156002; -.
DR HOGENOM; CLU_005790_3_0_1; -.
DR InParanoid; Q5DW34; -.
DR OMA; ACLCWKD; -.
DR OrthoDB; 5792673at2759; -.
DR PhylomeDB; Q5DW34; -.
DR BRENDA; 2.1.1.367; 3474.
DR BRENDA; 2.1.1.368; 3474.
DR Reactome; R-MMU-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR Reactome; R-MMU-3214841; PKMTs methylate histone lysines.
DR Reactome; R-MMU-6804760; Regulation of TP53 Activity through Methylation.
DR Reactome; R-MMU-8953750; Transcriptional Regulation by E2F6.
DR BioGRID-ORCS; 77683; 20 hits in 86 CRISPR screens.
DR PRO; PR:Q5DW34; -.
DR Proteomes; UP000000589; Chromosome 2.
DR RNAct; Q5DW34; protein.
DR Bgee; ENSMUSG00000036893; Expressed in manus and 230 other cell types or tissues.
DR ExpressionAtlas; Q5DW34; baseline and differential.
DR GO; GO:0000785; C:chromatin; IDA:UniProtKB.
DR GO; GO:0005694; C:chromosome; EXP:UniProtKB.
DR GO; GO:0016604; C:nuclear body; ISO:GO_Central.
DR GO; GO:0005654; C:nucleoplasm; ISO:GO_Central.
DR GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR GO; GO:0070742; F:C2H2 zinc finger domain binding; IPI:UniProtKB.
DR GO; GO:0046976; F:histone H3K27 methyltransferase activity; IDA:UniProtKB.
DR GO; GO:0140942; F:histone H3K9 dimethyltransferase activity; IDA:UniProtKB.
DR GO; GO:0046974; F:histone H3K9 methyltransferase activity; IDA:UniProtKB.
DR GO; GO:0140948; F:histone H3K9 monomethyltransferase activity; EXP:UniProtKB.
DR GO; GO:0140949; F:histone H3K9 trimethyltransferase activity; IDA:UniProtKB.
DR GO; GO:0140947; F:histone H3K9me2 methyltransferase activity; EXP:UniProtKB.
DR GO; GO:0008168; F:methyltransferase activity; ISO:GO_Central.
DR GO; GO:0002039; F:p53 binding; ISO:GO_Central.
DR GO; GO:0016279; F:protein-lysine N-methyltransferase activity; ISO:GO_Central.
DR GO; GO:0001222; F:transcription corepressor binding; ISO:GO_Central.
DR GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR GO; GO:0160274; P:beige fat cell differentiation; IDA:UniProtKB.
DR GO; GO:0050873; P:brown fat cell differentiation; IDA:UniProtKB.
DR GO; GO:0006325; P:chromatin organization; ISO:GO_Central.
DR GO; GO:0006346; P:DNA methylation-dependent constitutive heterochromatin formation; IDA:UniProtKB.
DR GO; GO:0040029; P:epigenetic regulation of gene expression; IBA:GO_Central.
DR GO; GO:0140718; P:facultative heterochromatin formation; IDA:GO_Central.
DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB.
DR GO; GO:0051148; P:negative regulation of muscle cell differentiation; IDA:UniProtKB.
DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:MGI.
DR GO; GO:0160275; P:negative regulation of white fat cell differentiation; IDA:UniProtKB.
DR GO; GO:0018027; P:peptidyl-lysine dimethylation; IMP:UniProtKB.
DR GO; GO:0018026; P:peptidyl-lysine monomethylation; IMP:UniProtKB.
DR GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; IMP:YuBioLab.
DR GO; GO:0050821; P:protein stabilization; IDA:UniProtKB.
DR GO; GO:0045995; P:regulation of embryonic development; IMP:UniProtKB.
DR CDD; cd20905; EHMT_ZBD; 1.
DR CDD; cd10535; SET_EHMT1; 1.
DR FunFam; 2.170.270.10:FF:000005; Euchromatic histone-lysine N-methyltransferase 2; 1.
DR FunFam; 1.25.40.20:FF:000029; histone-lysine N-methyltransferase EHMT1 isoform X2; 1.
DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1.
DR Gene3D; 2.170.270.10; SET domain; 1.
DR InterPro; IPR002110; Ankyrin_rpt.
DR InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR InterPro; IPR043550; EHMT1/EHMT2.
DR InterPro; IPR047762; EHMT_CRR.
DR InterPro; IPR007728; Pre-SET_dom.
DR InterPro; IPR001214; SET_dom.
DR InterPro; IPR046341; SET_dom_sf.
DR InterPro; IPR038035; SET_EHMT1.
DR PANTHER; PTHR46307; G9A, ISOFORM B; 1.
DR PANTHER; PTHR46307:SF2; HISTONE-LYSINE N-METHYLTRANSFERASE EHMT1; 1.
DR Pfam; PF12796; Ank_2; 2.
DR Pfam; PF13637; Ank_4; 1.
DR Pfam; PF21533; EHMT1-2_CRR; 1.
DR Pfam; PF05033; Pre-SET; 1.
DR Pfam; PF00856; SET; 1.
DR PRINTS; PR01415; ANKYRIN.
DR SMART; SM00248; ANK; 7.
DR SMART; SM00468; PreSET; 1.
DR SMART; SM00317; SET; 1.
DR SUPFAM; SSF48403; Ankyrin repeat; 1.
DR SUPFAM; SSF82199; SET domain; 1.
DR PROSITE; PS50297; ANK_REP_REGION; 1.
DR PROSITE; PS50088; ANK_REPEAT; 5.
DR PROSITE; PS50867; PRE_SET; 1.
DR PROSITE; PS50280; SET; 1.
PE 1: Evidence at protein level;
KW Acetylation; Alternative splicing; ANK repeat; Chromatin regulator;
KW Chromosome; Isopeptide bond; Metal-binding; Methyltransferase; Nucleus;
KW Phosphoprotein; Reference proteome; Repeat; S-adenosyl-L-methionine;
KW Transferase; Ubl conjugation; Zinc.
FT INIT_MET 1
FT /note="Removed"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CHAIN 2..1296
FT /note="Histone-lysine N-methyltransferase EHMT1"
FT /id="PRO_0000405844"
FT REPEAT 735..764
FT /note="ANK 1"
FT REPEAT 770..799
FT /note="ANK 2"
FT REPEAT 803..832
FT /note="ANK 3"
FT REPEAT 836..866
FT /note="ANK 4"
FT REPEAT 870..899
FT /note="ANK 5"
FT REPEAT 903..932
FT /note="ANK 6"
FT REPEAT 936..965
FT /note="ANK 7"
FT REPEAT 969..1002
FT /note="ANK 8"
FT DOMAIN 1058..1121
FT /note="Pre-SET"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00157"
FT DOMAIN 1124..1241
FT /note="SET"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00190"
FT REGION 1..111
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 170..200
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 341..470
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 653..714
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 903..905
FT /note="Histone H3K9me binding"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT REGION 1160..1179
FT /note="Interaction with histone H3"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT REGION 1240..1243
FT /note="Interaction with histone H3"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT REGION 1271..1296
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 14..31
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 77..89
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 97..106
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 342..360
FT /note="Acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 371..391
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 392..414
FT /note="Acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 438..450
FT /note="Basic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT BINDING 1060
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="1"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1060
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="2"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1062
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="1"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1066
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="1"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1066
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="3"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1071
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="1"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1073
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="2"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1103
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="2"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1103
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="3"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1107
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="2"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1109
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="3"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1113
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="3"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1134..1136
FT /ligand="S-adenosyl-L-methionine"
FT /ligand_id="ChEBI:CHEBI:59789"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1171
FT /ligand="S-adenosyl-L-methionine"
FT /ligand_id="ChEBI:CHEBI:59789"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00190"
FT BINDING 1198..1199
FT /ligand="S-adenosyl-L-methionine"
FT /ligand_id="ChEBI:CHEBI:59789"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1201
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="4"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1254
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="4"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1255
FT /ligand="S-adenosyl-L-methionine"
FT /ligand_id="ChEBI:CHEBI:59789"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00190"
FT BINDING 1256
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="4"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT BINDING 1261
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /ligand_label="4"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT SITE 1153
FT /note="Histone H3K9me binding"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT MOD_RES 2
FT /note="N-acetylalanine"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT MOD_RES 433
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT MOD_RES 481
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT MOD_RES 1046
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CROSSLNK 23
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO1); alternate"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CROSSLNK 23
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2); alternate"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CROSSLNK 191
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2)"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CROSSLNK 229
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2)"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CROSSLNK 232
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2)"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CROSSLNK 315
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2)"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CROSSLNK 325
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2)"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CROSSLNK 430
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2)"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CROSSLNK 559
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2)"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CROSSLNK 644
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2)"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CROSSLNK 659
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2)"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT CROSSLNK 729
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2)"
FT /evidence="ECO:0000250|UniProtKB:Q9H9B1"
FT VAR_SEQ 273..279
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:15489334"
FT /id="VSP_040724"
FT VAR_SEQ 455..500
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:15489334"
FT /id="VSP_040725"
FT VAR_SEQ 550..597
FT /note="Missing (in isoform 3)"
FT /evidence="ECO:0000303|PubMed:15489334"
FT /id="VSP_040726"
FT MUTAGEN 1153
FT /note="Y->V: In LM7; does not prevent methyltransferase
FT activity; when associated with F-1240."
FT /evidence="ECO:0000269|PubMed:18818694"
FT MUTAGEN 1198..1201
FT /note="Missing: In LM3; does not form heterodimer with
FT EHMT2 and is defective in mediating both H3K9me and DNA
FT methylation."
FT /evidence="ECO:0000269|PubMed:18818694"
FT MUTAGEN 1198..1199
FT /note="NH->LE: Abolished histone methyltransferase
FT activity, preventing differentiation of brown adipose
FT cells."
FT /evidence="ECO:0000269|PubMed:24196706"
FT MUTAGEN 1201
FT /note="C->A: In LM4; does not prevent methyltransferase
FT activity."
FT /evidence="ECO:0000269|PubMed:18818694"
FT MUTAGEN 1240
FT /note="Y->F: In LM7; does not prevent methyltransferase
FT activity; when associated with V-1153."
FT /evidence="ECO:0000269|PubMed:18818694"
FT CONFLICT 411
FT /note="E -> D (in Ref. 1; BAD90007)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 1296 AA; 141999 MW; B7783B6F38D3C7CB CRC64;
MAAADAEQAV LAKQETKQDC CMKTELLRED TPMAADEGST EKQEGETPMA ADGETNGSCE
KSGDPSHLNA PKHTQENTRA SPQEGTNRVS RVAENGVSER DTEVGKQNHV TADDFMQTSV
IGSNGYFLNK PALQGQPLRT PNILTSSLPG HAAKTLPGGA SKCRTLSALP QTPTTAPTVP
GEGSADTEDR KPTASGTDVR VHRARKTMPK SILGLHAASK DHREVQDHKE PKEDINRNIS
ECGRQQLLPT FPALHQSLPQ NQCYMATTKS QTACLPFVLA AAVSRKKKRR MGTYSLVPKK
KTKVLKQRTV IEMFKSITHS TVGAKGEKAL DDSALHVNGE SLEMDSEDED SDELEDDEDH
GAEQAAAFPT EDSRTSKESM SETDRAAKMD GDSEEEQESP DTGEDEDGGD ESDLSSESSI
KKKFLKRRGK TDSPWIKPAR KRRRRSRKKP SSMLGSEACK SSPGSMEQAA LGDSAGYMEV
SLDSLDLRVR GILSSQTENE GLASGPDVLG TDGLQEVPLC SCRMETPKSR EISTLANNQC
MATESVDHEL GRCTNSVVKY ELMRPSNKAP LLVLCEDHRG RMVKHQCCPG CGYFCTAGNF
MECQPESSIS HRFHKDCASR VNNASYCPHC GEEASKAKEV TIAKADTTST VTLAPGQEKS
LAAEGRADTT TGSIAGAPED ERSQSTAPQA PECFDPAGPA GLVRPTSGLS QGPGKETLES
ALIALDSEKP KKLRFHPKQL YFSARQGELQ KVLLMLVDGI DPNFKMEHQS KRSPLHAAAE
AGHVDICHML VQAGANIDTC SEDQRTPLME AAENNHLDAV KYLIKAGAQV DPKDAEGSTC
LHLAAKKGHY DVVQYLLSNG QMDVNCQDDG GWTPMIWATE YKHVELVKLL LSKGSDINIR
DNEENICLHW AAFSGCVDIA EILLAAKCDL HAVNIHGDSP LHIAARENRY DCVVLFLSRD
SDVTLKNKEG ETPLQCASLS SQVWSALQMS KALRDSAPDK PVAVEKTVSR DIARGYERIP
IPCVNAVDSE LCPTNYKYVS QNCVTSPMNI DRNITHLQYC VCVDDCSSST CMCGQLSMRC
WYDKDGRLLP EFNMAEPPLI FECNHACSCW RNCRNRVVQN GLRARLQLYR TQDMGWGVRS
LQDIPLGTFV CEYVGELISD SEADVREEDS YLFDLDNKDG EVYCIDARFY GNVSRFINHH
CEPNLVPVRV FMSHQDLRFP RIAFFSTRLI QAGEQLGFDY GERFWDVKGK LFSCRCGSSK
CRHSSAALAQ RQASAAQEPQ ENGLPDTSSA AAADPL
//